--- title: "Enzon Extends Exchange Offer Amid Pending Viskase Merger" type: "News" locale: "en" url: "https://longbridge.com/en/news/279321020.md" description: "Enzon Pharmaceuticals has extended the expiration date of its exchange offer for Series C Non-Convertible Redeemable Preferred Stock to March 19, 2026, as part of its merger with Viskase Companies, Inc. The merger is subject to regulatory and shareholder approvals, with various risks including potential litigation and operational disruptions. Enzon aims to create a combined entity with its common stock quoted on the OTCQB tier. Current market cap stands at $4.23M." datetime: "2026-03-16T20:35:16.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/279321020.md) - [en](https://longbridge.com/en/news/279321020.md) - [zh-HK](https://longbridge.com/zh-HK/news/279321020.md) --- # Enzon Extends Exchange Offer Amid Pending Viskase Merger ### Claim 70% Off TipRanks Premium - Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions - Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential The latest announcement is out from Enzon Pharmaceuticals ( (ENZN) ). On March 16, 2026, Enzon Pharmaceuticals announced it has extended the expiration date of its exchange offer to holders of its Series C Non-Convertible Redeemable Preferred Stock, who are being offered Enzon common shares in exchange for their preferred holdings. The offer will now expire at 5:00 p.m. Eastern time on March 19, 2026, unless further extended, and forms part of the broader capital and corporate restructuring associated with Enzon’s planned merger with Viskase Companies, Inc., for which a detailed registration statement containing information on the combined company has been filed with the SEC. The announcement underscores that the merger remains subject to various closing conditions and regulatory and shareholder approvals, and highlights a wide range of transaction risks, including timing uncertainties, potential litigation, operational disruptions, and the possibility that expected financial and strategic benefits of the combination may not be realized, factors that are material for current and prospective stakeholders evaluating Enzon’s evolving risk profile and ownership structure. **More about Enzon Pharmaceuticals** Enzon Pharmaceuticals operates in the pharmaceutical and biotechnology industry, historically focused on developing and commercializing therapeutics, with its securities traded on over-the-counter markets. The company is currently pursuing a strategic combination with Viskase Companies, Inc., aiming to create a combined entity whose common stock is expected to be quoted on the OTCQB tier, subject to customary conditions and approvals. **Average Trading Volume:** 71,919 **Technical Sentiment Signal:** Sell **Current Market Cap:** $4.23M For a thorough assessment of ENZN stock, go to TipRanks’ Stock Analysis page. ### Related Stocks - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [IHE.US](https://longbridge.com/en/quote/IHE.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [ENZ.US](https://longbridge.com/en/quote/ENZ.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [ENZB.US](https://longbridge.com/en/quote/ENZB.US.md) - [XLV.US](https://longbridge.com/en/quote/XLV.US.md) ## Related News & Research - [](https://longbridge.com/en/news/286807703.md) - [Sun Pharma signs Definitive Agreement to Acquire Organon | OGN Stock News](https://longbridge.com/en/news/284127453.md) - [14:05 ETLupin Receives Tentative Approval from U.S. FDA for Revefenacin Inhalation Solution](https://longbridge.com/en/news/286805922.md) - [NeOnc Advances Glioma Programs and Strengthens Financial Position](https://longbridge.com/en/news/286826865.md) - [CSPC Wins U.S. FDA Trial Nod for First-in-Class KAT6 Cancer Drug](https://longbridge.com/en/news/284000142.md)